Geneva, June 4 -- International Clinical Trials Registry received information related to the study (NCT06987851) titled 'An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD' on May 16.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Biocad
Condition:
Multiple Sclerosis
Intervention:
Biological: Divozilimab
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: March 22, 2022
Target Sample Size: 44
Countries of Recruitment:
Russian Federation
To know more, visit...